Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8951293 | 1.00 | ALDH1A1 (0.51) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| SCHEMBL10440320 | 0.90 | ALDH1A1 (0.45) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| SCHEMBL7269272 | 0.87 | TAS1R3 (0.51) | ALDH1A1FOLH1CASP1 | |
| SCHEMBL7269277 | 0.87 | TAS1R3 (0.51) | ALDH1A1FOLH1CASP1 | |
| SCHEMBL733515 | 0.86 | ALDH1A1 (0.47) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| SCHEMBL29398811 | 0.86 | CASP1 (0.47) | ALDH1A1FOLH1MEN1LMNAKMT2A | |
| SCHEMBL15107083 | 0.84 | SMN1; SMN2 (0.49) | ALDH1A1TYRCASP1 | |
| SCHEMBL13118364 | 0.83 | CASP1 (0.46) | ALDH1A1CASP1 | |
| SCHEMBL29624611 | 0.83 | CASP1 (0.46) | ALDH1A1CASP1 | |
| SCHEMBL10440429 | 0.83 | CASP1 (0.45) | ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12625431-B2 | EUV resist underlayer film-forming composition | NISSAN CHEMICAL CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| CN-115053184-B | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2024-12-06 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20230098881-A1 | EUV RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-03-30 | — | — | US | disclosed |
| US-11590232-B2 | Bioconjugates of neuropeptides derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-02-28 | — | — | US | disclosed |
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-2545033-A2 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112535-A2 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | ALBANY MOLECULAR RESEARCH, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| US-5541290-A | OLIGOPEPTIDE CONTAINING ALPHA-KETOAMIDE GROUP, TREATMENT OF ALZHEIMER*S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS | CORTEX PHARMACEUTICALS, INC. | 1996-07-30 | — | — | US | disclosed |
| WO-1995000535-A1 | OPTICALLY PURE CALPAIN INHIBITOR COMPOUNDS | ALKERMES, INCORPORATED (US) | 1995-01-05 | — | — | WO | disclosed |
| US-4977272-A | Radiation absorbers | THE STANDARD OIL COMPANY (US) | 1990-12-11 | — | — | US | disclosed |
| US-4868061-A | ADDITION POLYMERS, ULTRAVIOLET RADIATION STABILIZERS | THE STANDARD OIL COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | ALDH1A1 589/4885FOLH1 63/4885MEN1 2448/4885 |
| US-12625431-B2 | EUV resist underlayer film-forming composition | EEF1A1, ARF1, EMG1 | ALDH1A1 2046/4885FOLH1 4643/4885MEN1 1846/4885 |
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | PCCA, PC, PMP22 | ALDH1A1 526/4885FOLH1 2104/4885MEN1 474/4885 |
| US-11590232-B2 | Bioconjugates of neuropeptides derivatives | VIP, NGLY1, NPSR1 | ALDH1A1 3075/4885FOLH1 56/4885MEN1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.